Reta+Cagri is a combination of reta and cagrilintide, two investigational compounds being studied for metabolic regulation. Retatrutide targets GLP-1, GIP, and glucagon receptors, while cagrilintide is an amylin analogue. Their combined effects are of research interest in appetite and metabolic pathways. This combination is not an established approved treatment.